M&A

Genentech Drops The Other Shoe

We all knew it was just a matter of time until the “special committee” appointed to review the Roche officially rejected the buyout offer of $89/share.

The press release indicates a willingness to listen to offers that “recognizes the value of the company and reflects the significant benefits that would accrue” to an acquiring company.

Move along folks, nothing to see here.

I’m calling $103/share.

Any guesses as to whether Roche will up the bid? By how Much?

Theoretically Related Posts

• July 23, 2008 -- Roche on Spending Spree (0)
• July 21, 2008 -- Will Roche Kill Independent Genentech? (0)
• September 10, 2008 -- ImClone Throws Down and Announces Additional Suitor (0)
• September 2, 2008 -- Shionogi Acquires Sciele Pharma for $1.4 Billion (0)
• August 22, 2008 -- King Tenders All Cash $1.4B Unsolicited Bid For Alphama (0)
• July 7, 2008 -- Shire Ponies Up For Jerini (0)
• June 19, 2008 -- ThromboGenics and BioInvent Ink Deal With Roche (0)
• May 6, 2008 -- Bristol-Myers Squibb To Be Acquired By… [Insert Name Here]?? (5)
• November 10, 2008 -- ArQule and Daiichi Sankyo Ink c-Met and Discovery Deals (0)
• October 30, 2008 -- GlaxoSmithKline to acquires Genelabs Technologies for $57M (0)

© 2008 Pharmababble.